GlassScriptPhysician profile
Bruce A Jones
NPI 1275526675
$3,443.30
in general payments reported to CMS, 2019-2025
34 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $368 · 2021: $310 · 2022: $635 · 2023: $606 · 2024: $420 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Education: $33.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.82 |
| Education | $33.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.33 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $353.30 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $257.94 | 2019-2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $221.45 | 2021-2022 | |
| Pfizer INC. | $121.30 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $101.79 | 2019-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $97.88 | 2019-2024 | Dificid, Zerbaxa |
| Genzyme Corporation | $97.88 | 2022-2024 | |
| Celgene Corporation | $84.02 | 2023-2024 | Zeposia |
| Allergan, INC. | $76.67 | 2019 | |
| Janssen Scientific Affairs, LLC | $73.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.74 | 2022 | |
| Gilead Sciences, INC. | $63.44 | 2019-2024 | |
| Ardelyx, INC. | $57.37 | 2022-2024 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $53.91 | 2022-2025 | Rebyota |
| Tersera Therapeutics LLC | $53.14 | 2021-2023 | Xermelo |
| Regeneron Healthcare Solutions, INC. | $48.32 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.46 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $44.67 | 2020-2021 | |
| Ucb, INC. | $44.45 | 2019-2020 | |
| Shionogi INC | $31.26 | 2019 | |
| Ironwood Pharmaceuticals, INC | $30.47 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $27.13 | 2024 | Bylvay, Iqirvo |
| Daiichi Sankyo INC. | $26.06 | 2022 | |
| Lilly USA, LLC | $25.18 | 2024 | Omvoh |
| Amgen INC. | $22.95 | 2023 | Amjevita |
| Shire North American Group INC | $22.46 | 2019 | |
| Medtronic, INC. | $19.17 | 2023 | Nexpowder |
| Aimmune Therapeutics, INC. | $18.77 | 2025 | Zenpep |
| Organon LLC | $18.16 | 2023 | Hadlima |
| Fresenius Kabi USA, LLC | $17.53 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $17.27 | 2021 | |
| Alfasigma USA, INC. | $15.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.